Conference Proceedings
Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)
Yuqin Song, Luis Malpica, Qingqing Cai, Weili Zhao, Keshu Zhou, Jianqiu Wu, Huilai Zhang, Kaiyang Ding, Yao Liu, Zengjun Li, Neha Mehta-Shah, Liling Zhang, Meifang Zheng, Jie Jin, Haiyan Yang, Yuerong Shuang, Dok Hyun Yoon, Sujun Gao, Wenyu Li, Zhimin Zhai Show all
BLOOD | ELSEVIER | Published : 2023
Abstract
Introduction: Golidocitinib is the first JAK1 selective inhibitor to enter into pivotal clinical development for the treatment of relapsed/refractory peripheral T cell lymphoma (r/r PTCL). Preliminary analysis of the JACKPOT8 study (NCT04105010) has shown promising antitumor efficacy and a manageable safety profile of golidocitinib. Here we reported the full analysis of the phase 2 multinational pivotal study JACKPOT8 Part B. Methods: This study enrolled r/r PTCL patients who had undergone at least one line of systemic therapies. All patients received golidocitinib at 150 mg once daily (QD) until disease progression or pre-defined discontinuation ..
View full abstract